Immunoassay Market by Product (Reagents & Kits, Analyzers), Technology (ELISA, Rapid Test, Western Blotting, ELISPOT), Specimen (Blood, Saliva), Application (Infectious Diseases, Oncology), End User (Hospitals & Clinics) - Global Forecasts to 2027

TABLE OF CONTENTS

"1    INTRODUCTION    44
1.1    STUDY OBJECTIVES    44
1.2    MARKET DEFINITION    44
1.2.1    INCLUSIONS & EXCLUSIONS    44
1.3    MARKET SCOPE    45
FIGURE 1    IMMUNOASSAY MARKET    45
1.3.1    YEARS CONSIDERED    46
1.4    CURRENCY CONSIDERED    46
1.5    STAKEHOLDERS    46
1.6    SUMMARY OF CHANGES    47
2    RESEARCH METHODOLOGY    48
2.1    RESEARCH DATA    48
FIGURE 2    RESEARCH DESIGN    48
2.1.1    SECONDARY DATA    49
2.1.1.1    Secondary sources    50
2.1.2    PRIMARY DATA    50
2.1.2.1    Key data from primary sources    51
2.1.2.2    Key industry insights    52
FIGURE 3    BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS    53
FIGURE 4    BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION    53
2.2    MARKET SIZE ESTIMATION    53
2.2.1    BOTTOM-UP APPROACH    54
FIGURE 5    MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH    54
FIGURE 6    MARKET SIZE ESTIMATION: TOP-DOWN APPROACH    55
FIGURE 7    CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS    55
2.3    MARKET BREAKDOWN AND DATA TRIANGULATION    56
FIGURE 8    DATA TRIANGULATION METHODOLOGY    56
2.4    MARKET SHARE ANALYSIS    57
2.5    STUDY ASSUMPTIONS    57
2.6    RISK ASSESSMENT    57
TABLE 1    RISK ASSESSMENT: IMMUNOASSAY MARKET    57
2.7    LIMITATIONS    58
2.7.1    METHODOLOGY-RELATED LIMITATIONS    58
2.7.2    SCOPE-RELATED LIMITATIONS    58
2.8    GROWTH RATE ASSUMPTIONS    58
3    EXECUTIVE SUMMARY    59
FIGURE 9    IMMUNOASSAY MARKET, BY PRODUCT, 2022 VS. 2027 (USD BILLION)    59
FIGURE 10    IMMUNOASSAY MARKET, BY TECHNOLOGY, 2022 VS. 2027 (USD BILLION)    60
FIGURE 11    IMMUNOASSAY MARKET, BY SPECIMEN, 2022 VS. 2027 (USD BILLION)    61
FIGURE 12    IMMUNOASSAY MARKET, BY APPLICATION, 2022 VS. 2027 (USD BILLION)    62
FIGURE 13    IMMUNOASSAY MARKET, BY END USER, 2022 VS. 2027 (USD BILLION)    63
FIGURE 14    GEOGRAPHICAL SNAPSHOT OF IMMUNOASSAY MARKET    64
4    PREMIUM INSIGHTS    65
4.1    IMMUNOASSAY MARKET OVERVIEW    65
FIGURE 15    RISING DISEASE INCIDENCE AND TECHNOLOGICAL ADVANCEMENTS—KEY DRIVERS OF MARKET GROWTH    65
4.2    NORTH AMERICA: IMMUNOASSAY MARKET, BY PRODUCT & COUNTRY (2021)    66
FIGURE 16    REAGENTS & KITS ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN MARKET IN 2021    66
4.3    IMMUNOASSAY MARKET: GEOGRAPHICAL SNAPSHOT    67
FIGURE 17    CHINA & INDIA TO WITNESS HIGHEST GROWTH RATES DURING FORECAST PERIOD    67
4.4    IMMUNOASSAY MARKET: GEOGRAPHIC MIX    68
FIGURE 18    APAC TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD    68
4.5    IMMUNOASSAY MARKET: DEVELOPED VS. DEVELOPING MARKETS    69
FIGURE 19    DEVELOPING MARKETS TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD    69
5    MARKET OVERVIEW    70
5.1    INTRODUCTION    70
5.2    MARKET DYNAMICS    70
FIGURE 20    IMMUNOASSAY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES    70
5.2.1    DRIVERS    71
5.2.1.1    Increasing incidence of chronic and infectious diseases and growing awareness about early disease diagnosis    71
FIGURE 21    INCIDENCE OF DIABETES, BY REGION, 2019 VS. 2030 VS. 2045 (MILLION)    71
TABLE 2    GLOBAL INCIDENCE OF INFECTIOUS DISEASES    72
5.2.1.1.1    Increasing use of immunoassays in oncology    72
TABLE 3    GLOBAL INCIDENCE OF TOP CANCERS IN MEN, 2020    73
TABLE 4    GLOBAL INCIDENCE OF TOP CANCERS IN WOMEN, 2020    73
5.2.1.1.2    Immunoassays for COVID-19 and other viral diagnostics    74
5.2.1.1.3    Immunoassays in drug detection and other diagnostic applications    74
TABLE 5    DETECTION OF DRUGS BY URINE TESTING    75
5.2.1.1.4    Growing geriatric population    75
FIGURE 22    GLOBAL AGING POPULATION, BY REGION, 2019 VS. 2050 (MILLION)    75
5.2.1.2    Advancements in systems and technologies    76
5.2.1.3    Growth in biotechnology and biopharmaceutical industries    77
5.2.1.4    Increasing adoption of immunoassay-based POC testing and rapid testing    77
TABLE 6    RECENT WAIVERS OF MARKET PRODUCTS    78
5.2.1.5    Supportive government policies    79
5.2.1.6    Increasing drug and alcohol abuse and stringent laws mandating drug and alcohol testing    79
5.2.2    RESTRAINTS    80
5.2.2.1    Stringent requirements for approval of immunoassay instruments and consumables    80
5.2.2.2    Technical hurdles of immunoassay kits    80
5.2.3    OPPORTUNITIES    81
5.2.3.1    Growth opportunities in emerging economies    81
5.2.3.2    Importance of companion diagnostics    82
TABLE 7    COMPANION DIAGNOSTIC ASSAYS APPROVED AND LAUNCHED    83
5.2.3.3    Development of condition-specific biomarkers and tests    83
TABLE 8    NEW TESTS LAUNCHED BY KEY PLAYERS    84
5.2.3.4    Integration of microfluidics in immunoassays    84
TABLE 9    LAB-ON-A-CHIP IMMUNOASSAYS/DEVICES/SYSTEMS OFFERED BY PLAYERS    85
5.2.3.5    Improving immunoassay diagnostic technologies    85
5.2.4    CHALLENGES    85
5.2.4.1    Design challenges, complexities, and quality of antibodies    85
5.2.4.2    Dearth of skilled professionals    86
5.2.4.3    Unfavorable reimbursement scenario    86
5.2.4.4    Financial hurdles faced by physicians    86
5.3    REGULATORY OVERVIEW    87
5.3.1    US    87
TABLE 10    US: CLASSIFICATION OF IMMUNOASSAY PRODUCTS    87
FIGURE 23    US: REGULATORY PROCESS FOR IVD DEVICES    88
5.3.2    CANADA    89
FIGURE 24    CANADA: REGULATORY PROCESS FOR IVD DEVICES IN CANADA    89
5.3.3    EUROPE    89
TABLE 11    EUROPE: CLASSIFICATION OF IVD DEVICES    89
5.3.4    JAPAN    90
5.3.4.1    Japan: Regulatory process for IVD devices    90
TABLE 12    JAPAN: CLASSIFICATION OF IVD REAGENTS IN JAPAN    91
TABLE 13    JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS    91
5.3.5    CHINA    91
TABLE 14    CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS    91
5.3.6    INDIA    92
5.3.6.1    India: Regulatory process for IVD devices    92
5.3.7    INDONESIA    93
TABLE 15    INDONESIA: REGISTRATION PROCESS FOR IVD DEVICES    93
5.3.8    RUSSIA    93
TABLE 16    RUSSIA: CLASSIFICATION OF IVD DEVICES    94
5.3.9    SAUDI ARABIA    94
TABLE 17    SAUDI ARABIA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS    94
5.3.10    MEXICO    94
5.3.10.1    Mexico: Regulatory process for IVD devices    95
TABLE 18    MEXICO: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS    95
5.3.11    BRAZIL    96
5.3.11.1    Brazil: Regulatory process for IVD devices    96
5.3.12    SOUTH KOREA    96
TABLE 19    SOUTH KOREA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS    96
5.3.13    MIDDLE EAST    97
5.3.14    AFRICA    97
5.4    TECHNOLOGY ANALYSIS    97
TABLE 20    CONVENTIONAL IMMUNOASSAY METHODS AND TECHNIQUES    97
TABLE 21    RECENT PRODUCT LAUNCHES WITH ADVANCED TECHNOLOGIES IN IMMUNOASSAY MARKET    98
5.5    TRADE ANALYSIS    98
5.5.1    TRADE ANALYSIS FOR IMMUNOASSAYS    98
TABLE 22    IMPORT DATA FOR HS CODE 902750, BY COUNTRY, 2017–2021 (USD MILLION)    99
TABLE 23    EXPORT DATA FOR HS CODE 902750, BY COUNTRY, 2016–2020 (USD MILLION)    99
5.6    PATENT ANALYSIS    100
5.7    VALUE CHAIN ANALYSIS    101
FIGURE 25    VALUE CHAIN ANALYSIS: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASES    101
5.8    SUPPLY CHAIN ANALYSIS    102
FIGURE 26    DIRECT DISTRIBUTION—PREFERRED STRATEGY FOR PROMINENT COMPANIES    102
5.9    ECOSYSTEM ANALYSIS OF IMMUNOASSAY MARKET    103
FIGURE 27    ECOSYSTEM ANALYSIS OF IMMUNOASSAY MARKET    103
5.9.1    ROLE IN ECOSYSTEM    103
5.9.2    KEY PLAYERS OPERATING IN IMMUNOASSAY MARKET    104
5.10    PORTER’S FIVE FORCES ANALYSIS    105
TABLE 24    HIGH CONSOLIDATION IN MARKET TO RESTRICT ENTRY OF NEW PLAYERS    105
5.10.1    DEGREE OF COMPETITION    105
5.10.2    BARGAINING POWER OF SUPPLIERS    105
5.10.3    BARGAINING POWER OF BUYERS    105
5.10.4    THREAT FROM SUBSTITUTES    105
5.10.5    THREAT FROM NEW ENTRANTS    106
5.11    KEY CONFERENCES & EVENTS IN 2022    106
TABLE 25    LIST OF CONFERENCES & EVENTS    106
5.12    PRICING ANALYSIS    107
TABLE 26    IMMUNOASSAY: PRICE RANGE FOR IMMUNOASSAY PRODUCTS    107
5.13    KEY STAKEHOLDERS & BUYING CRITERIA    108
5.13.1    KEY STAKEHOLDERS IN BUYING PROCESS    108
FIGURE 28    INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USER    108
TABLE 27    INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR END USERS    108
5.13.2    BUYING CRITERIA    109
FIGURE 29    KEY BUYING CRITERIA FOR TOP END USERS    109
TABLE 28    KEY BUYING CRITERIA, BY END USER    109
5.14    TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES    110
5.15    SCENARIO-BASED MARKET ASSESSMENT    111
5.15.1    IMMUNOASSAY MARKET FORECAST    111
FIGURE 30    PESSIMISTIC SCENARIO    111
FIGURE 31    OPTIMISTIC SCENARIO    111
FIGURE 32    REALISTIC SCENARIO    112
6    IMMUNOASSAY MARKET, BY PRODUCT    113
6.1    INTRODUCTION    114
TABLE 29    IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION)    114
6.2    REAGENTS & KITS    114
TABLE 30    IMMUNOASSAY REAGENTS & KITS AVAILABLE IN MARKET    115
TABLE 31    IMMUNOASSAY REAGENTS & KITS MARKET, BY REGION, 2020–2027 (USD MILLION)    116
TABLE 32    IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION)    116
6.2.1    ELISA REAGENTS & KITS    117
6.2.1.1    Wide usage in basic research and high-throughput screening    117
TABLE 33    ELISA REAGENTS & KITS MARKET, BY REGION, 2020–2027 (USD MILLION)    118
6.2.2    RAPID TEST REAGENTS & KITS    118
6.2.2.1    High demand for rapid test reagents & kits in remote areas to drive growth    118
TABLE 34    RAPID TEST REAGENTS & KITS MARKET, BY REGION, 2020–2027 (USD MILLION)    119
6.2.3    ELISPOT REAGENTS & KITS    119
6.2.3.1    High sensitivity, functionality, and adaptability of ELISpot technology to drive demand    119
TABLE 35    ELISPOT REAGENTS & KITS MARKET, BY REGION, 2020–2027 (USD MILLION)    120
6.2.4    WESTERN BLOT REAGENTS & KITS    120
6.2.4.1    Gold standard for result confirmation promotes Western blotting reagents & kits    120
TABLE 36    WESTERN BLOT REAGENTS & KITS MARKET, BY REGION, 2020–2027 (USD MILLION)    121
6.2.5    OTHER REAGENTS & KITS    121
TABLE 37    OTHER IMMUNOASSAY REAGENTS & KITS MARKET, BY REGION, 2020–2027 (USD MILLION)    122
6.3    ANALYZERS    122
TABLE 38    IMMUNOASSAY ANALYZERS AVAILABLE IN MARKET    123
TABLE 39    IMMUNOASSAY ANALYZERS MARKET, BY REGION, 2020–2027 (USD MILLION)    124
6.3.1    IMMUNOASSAY ANALYZERS MARKET, BY TYPE    124
TABLE 40    IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION)    125
6.3.1.1    Open-ended systems    125
6.3.1.1.1    Flexibility and wide availability make open-ended systems popular among users    125
TABLE 41    OPEN-ENDED SYSTEMS MARKET, BY REGION, 2020–2027 (USD MILLION)    125
6.3.1.2    Closed-ended systems    126
6.3.1.2.1    High precision and automation are key features of closed-ended systems    126
TABLE 42    CLOSED-ENDED SYSTEMS MARKET, BY REGION, 2020–2027 (USD MILLION)    126
6.3.2    IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE    126
TABLE 43    IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION)    126
6.3.2.1    Rental purchase    127
6.3.2.1.1    Convenience and lack of liability for end users drive preference for device rental    127
TABLE 44    RENTAL PURCHASE IMMUNOASSAY ANALYZERS MARKET, BY REGION, 2020–2027 (USD MILLION)    127
6.3.2.2    Outright purchase    128
6.3.2.2.1    Outright purchase is favored by government organizations, big companies, and CROs    128
TABLE 45    OUTRIGHT PURCHASE IMMUNOASSAY ANALYZERS MARKET, BY REGION, 2020–2027 (USD MILLION)    128
7    IMMUNOASSAY MARKET, BY TECHNOLOGY    129
7.1    INTRODUCTION    130
TABLE 46    IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)    130
7.2    ELISA    130
TABLE 47    KEY ELISA SYSTEMS AVAILABLE IN MARKET    131
TABLE 48    IMMUNOASSAY MARKET FOR ELISA, BY REGION, 2020–2027 (USD MILLION)    132
7.2.1    ELISA MARKET, BY GENERATION    132
TABLE 49    IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION)    132
7.2.1.1    Third-generation & above    133
7.2.1.1.1    Third- & fourth-gen ELISA show high specificity and accuracy    133
TABLE 50    THIRD-GENERATION & ABOVE ELISA MARKET, BY REGION, 2020–2027 (USD MILLION)    133
7.2.1.2    Second-generation & below    134
7.2.1.2.1    Cost-effectiveness of first- and second-generation tests supports their use    134
TABLE 51    SECOND-GENERATION & BELOW ELISA MARKET, BY REGION, 2020–2027 (USD MILLION)    134
7.2.2    ELISA MARKET, BY TYPE    135
TABLE 52    IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION)    135
7.2.2.1    CLIA    135
7.2.2.1.1    CLIA holds largest share of ELISA market, by type    135
TABLE 53    CLIA MARKET, BY REGION, 2020–2027 (USD MILLION)    136
7.2.2.2    IFA    136
7.2.2.2.1    IFA is used to diagnose antibodies against infectious pathogens    136
TABLE 54    IFA MARKET, BY REGION, 2020–2027 (USD MILLION)    137
7.2.2.3    Colorimetric immunoassays    137
7.2.2.3.1    Introduction of advanced techniques will support market growth    137
TABLE 55    COLORIMETRIC IMMUNOASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION)    138
7.3    RAPID TESTS    138
7.3.1    WIDE USE OF RAPID TESTS IN EMERGING COUNTRIES OR AREAS WITH LIMITED TECHNOLOGY ACCESS TO DRIVE GROWTH    138
TABLE 56    KEY RAPID TESTS AVAILABLE IN MARKET    138
TABLE 57    IMMUNOASSAY MARKET FOR RAPID TESTS, BY REGION, 2020–2027 (USD MILLION)    139
7.4    WESTERN BLOTTING    140
7.4.1    WIDE USE IN RESULT CONFIRMATION AND ANTIBODY DETECTION RESPONSIBLE FOR MARKET GROWTH    140
TABLE 58    WESTERN BLOTTING SYSTEMS AVAILABLE IN MARKET    140
TABLE 59    IMMUNOASSAY MARKET FOR WESTERN BLOTTING, BY REGION, 2020–2027 (USD MILLION)    140
7.5    RADIOIMMUNOASSAYS    141
7.5.1    HIGH USAGE OF RIA FOR DIAGNOSIS AND DRUG TESTING TO DRIVE GROWTH    141
TABLE 60    IMMUNOASSAY MARKET FOR RADIOIMMUNOASSAYS, BY REGION, 2020–2027 (USD MILLION)    141
7.6    ELISPOT    141
7.6.1    HIGH SENSITIVITY, SPECIFICITY, AND VERSATILITY OF ELISPOT DRIVE ADOPTION OF ASSAYS    141
TABLE 61    IMMUNOASSAY MARKET FOR ELISPOT, BY REGION, 2020–2027 (USD MILLION)    142
7.7    OTHER TECHNOLOGIES    142
TABLE 62    IMMUNOASSAY MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2020–2027 (USD MILLION)    143
8    IMMUNOASSAY MARKET, BY SPECIMEN    144
8.1    INTRODUCTION    145
TABLE 63    IMMUNOASSAY MARKET, BY SPECIMEN, 2020–2027 (USD MILLION)    145
8.2    BLOOD    145
8.2.1    HIGH RELIABILITY OF BLOOD TESTS WILL ENSURE STABLE MARKET GROWTH    145
TABLE 64    IMMUNOASSAY MARKET FOR BLOOD SPECIMENS, BY REGION, 2020–2027 (USD MILLION)    146
8.3    SALIVA    147
8.3.1    CONVENIENCE AND APPLICATIONS OF SALIVA TESTS TO SUPPORT MARKET GROWTH    147
TABLE 65    IMMUNOASSAY MARKET FOR SALIVA SPECIMENS, BY REGION, 2020–2027 (USD MILLION)    147
8.4    URINE    148
8.4.1    USE IN LAW ENFORCEMENT AND DRUG TESTING APPLICATIONS DRIVES DEMAND FOR URINE-BASED TESTS    148
TABLE 66    IMMUNOASSAY MARKET FOR URINE SPECIMENS, BY REGION, 2020–2027 (USD MILLION)    148
8.5    OTHER SPECIMENS    149
TABLE 67    IMMUNOASSAY MARKET FOR OTHER SPECIMENS, BY REGION, 2020–2027 (USD MILLION)    149
9    IMMUNOASSAY MARKET, BY APPLICATION    150
9.1    INTRODUCTION    151
TABLE 68    IMMUNOASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)    151
9.2    INFECTIOUS DISEASES    152
9.2.1    RISING PREVALENCE OF INFECTIOUS DISEASES TO DRIVE MARKET GROWTH    152
TABLE 69    IMMUNOASSAY MARKET FOR INFECTIOUS DISEASES, BY REGION, 2020–2027 (USD MILLION)    152
9.3    ENDOCRINOLOGY    153
9.3.1    RISING GLOBAL DIABETES INCIDENCE WILL DRIVE DEMAND FOR IMMUNOASSAYS    153
TABLE 70    IMMUNOASSAY MARKET FOR ENDOCRINOLOGY APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)    153
9.4    CARDIOLOGY    154
9.4.1    HIGH BURDEN OF CVD TO SUPPORT MARKET GROWTH    154
TABLE 71    KEY PLAYERS AND IMMUNOASSAY PRODUCTS FOR CARDIOLOGY APPLICATIONS    154
TABLE 72    IMMUNOASSAY MARKET FOR CARDIOLOGY APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)    155
9.5    AUTOIMMUNE DISORDERS    155
9.5.1    RISING ECONOMIC BURDEN OF AUTOIMMUNE DISORDER TREATMENT—A KEY FACTOR DRIVING MARKET GROWTH    155
TABLE 73    IMMUNOASSAY MARKET FOR AUTOIMMUNE DISORDERS, BY REGION, 2020–2027 (USD MILLION)    156
9.6    ALLERGY DIAGNOSTICS    156
9.6.1    GROWING PREVALENCE OF ALLERGIES TO INCREASE DEMAND FOR IMMUNOASSAYS    156
TABLE 74    IMMUNOASSAY MARKET FOR ALLERGY DIAGNOSTICS, BY REGION, 2020–2027 (USD MILLION)    157
9.7    ONCOLOGY    157
9.7.1    RISING BURDEN OF CANCER—A POSITIVE INDICATOR OF MARKET GROWTH    157
TABLE 75    INCREASING INCIDENCE OF CANCER, BY REGION, 2020 VS. 2030 VS. 2040 (MILLION)    158
TABLE 76    IMMUNOASSAY MARKET FOR ONCOLOGY APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)    159
9.8    BONE & MINERAL DISORDERS    159
9.8.1    HIGH DISORDER PREVALENCE INDICATES STRONG GROWTH OPPORTUNITIES FOR IMMUNOASSAYS    159
TABLE 77    KEY PLAYERS AND IMMUNOASSAY PRODUCTS FOR BONE & MINERAL DISORDER DIAGNOSIS    160
TABLE 78    IMMUNOASSAY MARKET FOR BONE & MINERAL DISORDERS, BY REGION, 2020–2027 (USD MILLION)    160
9.9    TOXICOLOGY    160
9.9.1    DRUG ABUSE AND ILLICIT DRUG CONSUMPTION ENSURE DEMAND FOR IMMUNOASSAYS IN TOXICOLOGY    160
TABLE 79    KEY PLAYERS AND IMMUNOASSAY PRODUCTS FOR DRUG MONITORING    161
TABLE 80    KEY PLAYERS AND IMMUNOASSAY PRODUCTS FOR DRUGS-OF-ABUSE/TOXICOLOGY ASSAYS    161
TABLE 81    IMMUNOASSAY MARKET FOR TOXICOLOGY APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)    162
9.10    BLOOD SCREENING    162
9.10.1    RISING BLOOD DONATION VOLUMES FAVOR DEMAND FOR IMMUNOASSAYS    162
TABLE 82    IMMUNOASSAY MARKET FOR BLOOD SCREENING APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)    163
9.11    NEWBORN SCREENING    163
9.11.1    IMMUNOASSAYS USED AS FIRST-TIER NEWBORN SCREENING PROTOCOL—A MAJOR DRIVING FACTOR    163
TABLE 83    KEY PLAYERS AND IMMUNOASSAY PRODUCTS FOR NEWBORN SCREENING    164
TABLE 84    IMMUNOASSAY MARKET FOR NEWBORN SCREENING APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)    165
9.12    OTHER APPLICATIONS    165
TABLE 85    IMMUNOASSAY MARKET FOR OTHER APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)    166
10    IMMUNOASSAY MARKET, BY END USER    167
10.1    INTRODUCTION    168
TABLE 86    IMMUNOASSAY MARKET, BY END USER, 2020–2027 (USD MILLION)    168
10.2    HOSPITALS & CLINICS    168
10.2.1    GROWING PATIENT POPULATION AND TESTING VOLUMES DRIVE MARKET GROWTH    168
TABLE 87    IMMUNOASSAY MARKET FOR HOSPITALS & CLINICS, BY REGION, 2020–2027 (USD MILLION)    169
10.3    CLINICAL LABORATORIES    170
10.3.1    RISING CLINICAL TEST VOLUMES AND REQUIREMENTS SUPPORT USE OF IMMUNOASSAYS IN CLINICAL LABS    170
TABLE 88    IMMUNOASSAY MARKET FOR CLINICAL LABORATORIES, BY REGION, 2020–2027 (USD MILLION)    171
10.4    PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES AND CONTRACT RESEARCH ORGANIZATIONS    171
10.4.1    GROWING DRUG DISCOVERY AND CLINICAL STUDY ACTIVITY DRIVES DEMAND FOR IMMUNOASSAYS IN PHARMA-BIOTECH INDUSTRY    171
TABLE 89    IMMUNOASSAY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES AND CROS, BY REGION, 2020–2027 (USD MILLION)    172
10.5    HOME CARE SETTINGS    172
10.5.1    RELIANCE ON AT-HOME TESTS AND POC DIAGNOSTICS BOOSTS MARKET GROWTH    172
TABLE 90    IMMUNOASSAY MARKET FOR HOME CARE SETTINGS, BY REGION, 2020–2027 (USD MILLION)    173
10.6    BLOOD BANKS    173
10.6.1    RISING DEMAND FOR BLOOD AND GROWING BLOOD DONATION VOLUMES DRIVE USE OF IMMUNOASSAYS FOR SCREENING    173
TABLE 91    IMMUNOASSAY MARKET FOR BLOOD BANKS, BY REGION, 2020–2027 (USD MILLION)    174
10.7    RESEARCH & ACADEMIC LABORATORIES    174
10.7.1    RISING NUMBER OF COLLEGES & UNIVERSITIES DRIVES MARKET GROWTH    174
TABLE 92    IMMUNOASSAY MARKET FOR RESEARCH & ACADEMIC LABORATORIES, BY REGION, 2020–2027 (USD MILLION)    175
11    IMMUNOASSAY MARKET, BY REGION    176
11.1    INTRODUCTION    177
TABLE 93    IMMUNOASSAY MARKET, BY REGION, 2020–2027 (USD MILLION)    177
11.2    NORTH AMERICA    178
FIGURE 33    NORTH AMERICA: IMMUNOASSAY MARKET SNAPSHOT    179
TABLE 94    NORTH AMERICA: IMMUNOASSAY MARKET, BY COUNTRY, 2020–2027 (USD MILLION)    180
TABLE 95    NORTH AMERICA: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION)    180
TABLE 96    NORTH AMERICA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION)    181
TABLE 97    NORTH AMERICA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION)    181
TABLE 98    NORTH AMERICA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION)    182
TABLE 99    NORTH AMERICA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)    182
TABLE 100    NORTH AMERICA: IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION)    183
TABLE 101    NORTH AMERICA: IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION)    183
TABLE 102    NORTH AMERICA: IMMUNOASSAY MARKET, BY SPECIMEN, 2020–2027 (USD MILLION)    184
TABLE 103    NORTH AMERICA: IMMUNOASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)    184
TABLE 104    NORTH AMERICA: IMMUNOASSAY MARKET, BY END USER, 2020–2027 (USD MILLION)    185
11.2.1    US    185
11.2.1.1    US holds largest share in North American market    185
TABLE 105    US: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION)    186
TABLE 106    US: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION)    187
TABLE 107    US: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION)    187
TABLE 108    US: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION)    188
TABLE 109    US: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)    188
TABLE 110    US: IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION)    189
TABLE 111    US: IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION)    189
TABLE 112    US: IMMUNOASSAY MARKET, BY SPECIMEN, 2020–2027 (USD MILLION)    190
TABLE 113    US: IMMUNOASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)    190
TABLE 114    US: IMMUNOASSAY MARKET, BY END USER, 2020–2027 (USD MILLION)    191
11.2.2    CANADA    191
11.2.2.1    Initiatives undertaken by government bodies to support growth of market in Canada    191
TABLE 115    CANADA: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION)    192
TABLE 116    CANADA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION)    193
TABLE 117    CANADA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION)    193
TABLE 118    CANADA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION)    194
TABLE 119    CANADA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)    194
TABLE 120    CANADA: IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION)    195
TABLE 121    CANADA: IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION)    195
TABLE 122    CANADA: IMMUNOASSAY MARKET, BY SPECIMEN, 2020–2027 (USD MILLION)    196
TABLE 123    CANADA: IMMUNOASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)    196
TABLE 124    CANADA: IMMUNOASSAY MARKET, BY END USER, 2020–2027 (USD MILLION)    197
11.3    EUROPE    197
TABLE 125    EUROPE: IMMUNOASSAY MARKET, BY COUNTRY, 2020–2027 (USD MILLION)    198
TABLE 126    EUROPE: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION)    199
TABLE 127    EUROPE: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION)    199
TABLE 128    EUROPE: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION)    200
TABLE 129    EUROPE: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION)    200
TABLE 130    EUROPE: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)    201
TABLE 131    EUROPE: IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION)    201
TABLE 132    EUROPE: IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION)    202
TABLE 133    EUROPE: IMMUNOASSAY MARKET, BY SPECIMEN, 2020–2027 (USD MILLION)    202
TABLE 134    EUROPE: IMMUNOASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)    203
TABLE 135    EUROPE: IMMUNOASSAY MARKET, BY END USER, 2020–2027 (USD MILLION)    203
11.3.1    GERMANY    204
11.3.1.1    Germany holds largest share of EU immunoassay market    204
TABLE 136    GERMANY: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION)    205
TABLE 137    GERMANY: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION)    205
TABLE 138    GERMANY: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION)    206
TABLE 139    GERMANY: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION)    206
TABLE 140    GERMANY: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)    207
TABLE 141    GERMANY: IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION)    207
TABLE 142    GERMANY: IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION)    208
TABLE 143    GERMANY: IMMUNOASSAY MARKET, BY SPECIMEN, 2020–2027 (USD MILLION)    208
TABLE 144    GERMANY: IMMUNOASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)    209
TABLE 145    GERMANY: IMMUNOASSAY MARKET, BY END USER, 2020–2027 (USD MILLION)    209
11.3.2    ITALY    210
11.3.2.1    Growing geriatric population and increasing support for research to support market growth    210
TABLE 146    ITALY: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION)    210
TABLE 147    ITALY: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION)    211
TABLE 148    ITALY: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION)    211
TABLE 149    ITALY: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION)    212
TABLE 150    ITALY: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)    212
TABLE 151    ITALY: IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION)    213
TABLE 152    ITALY: IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION)    213
TABLE 153    ITALY: IMMUNOASSAY MARKET, BY SPECIMEN, 2020–2027 (USD MILLION)    214
TABLE 154    ITALY: IMMUNOASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)    214
TABLE 155    ITALY: IMMUNOASSAY MARKET, BY END USER, 2020–2027 (USD MILLION)    215
11.3.3    FRANCE    215
11.3.3.1    Rising use of POC testing and favorable reimbursement policies make France a lucrative market    215
TABLE 156    FRANCE: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION)    216
TABLE 157    FRANCE: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION)    216
TABLE 158    FRANCE: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION)    217
TABLE 159    FRANCE: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION)    217
TABLE 160    FRANCE: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)    218
TABLE 161    FRANCE: IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION)    218
TABLE 162    FRANCE: IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION)    219
TABLE 163    FRANCE: IMMUNOASSAY MARKET, BY SPECIMEN, 2020–2027 (USD MILLION)    219
TABLE 164    FRANCE: IMMUNOASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)    220
TABLE 165    FRANCE: IMMUNOASSAY MARKET, BY END USER, 2020–2027 (USD MILLION)    220
11.3.4    SPAIN    221
11.3.4.1    Increasing adoption of technologically advanced immunoassay systems makes Spain a relatively large market    221
TABLE 166    SPAIN: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION)    221
TABLE 167    SPAIN: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION)    222
TABLE 168    SPAIN: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION)    222
TABLE 169    SPAIN: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION)    223
TABLE 170    SPAIN: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)    223
TABLE 171    SPAIN: IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION)    224
TABLE 172    SPAIN: IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION)    224
TABLE 173    SPAIN: IMMUNOASSAY MARKET, BY SPECIMEN, 2020–2027 (USD MILLION)    225
TABLE 174    SPAIN: IMMUNOASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)    225
TABLE 175    SPAIN: IMMUNOASSAY MARKET, BY END USER, 2020–2027 (USD MILLION)    226
11.3.5    UK    226
11.3.5.1    Government support for disease diagnostics and favorable investment scenario drive market in UK    226
TABLE 176    UK: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION)    227
TABLE 177    UK: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION)    228
TABLE 178    UK: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION)    228
TABLE 179    UK: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION)    229
TABLE 180    UK: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)    229
TABLE 181    UK: IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION)    230
TABLE 182    UK: IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION)    230
TABLE 183    UK: IMMUNOASSAY MARKET, BY SPECIMEN, 2020–2027 (USD MILLION)    231
TABLE 184    UK: IMMUNOASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)    231
TABLE 185    UK: IMMUNOASSAY MARKET, BY END USER, 2020–2027 (USD MILLION)    232
11.3.6    RUSSIA    232
11.3.6.1    Lack of reimbursement and delays in approval may hinder market growth    232
TABLE 186    RUSSIA: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION)    233
TABLE 187    RUSSIA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION)    233
TABLE 188    RUSSIA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION)    234
TABLE 189    RUSSIA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION)    234
TABLE 190    RUSSIA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)    235
TABLE 191    RUSSIA: IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION)    235
TABLE 192    RUSSIA: IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION)    236
TABLE 193    RUSSIA: IMMUNOASSAY MARKET, BY SPECIMEN, 2020–2027 (USD MILLION)    236
TABLE 194    RUSSIA: IMMUNOASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)    237
TABLE 195    RUSSIA: IMMUNOASSAY MARKET, BY END USER, 2020–2027 (USD MILLION)    237
11.3.7    REST OF EUROPE    238
TABLE 196    REST OF EUROPE: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION)    238
TABLE 197    REST OF EUROPE: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION)    239
TABLE 198    REST OF EUROPE: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION)    239
TABLE 199    REST OF EUROPE: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION)    240
TABLE 200    REST OF EUROPE: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)    240
TABLE 201    REST OF EUROPE: IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION)    241
TABLE 202    REST OF EUROPE: IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION)    241
TABLE 203    REST OF EUROPE: IMMUNOASSAY MARKET, BY SPECIMEN, 2020–2027 (USD MILLION)    242
TABLE 204    REST OF EUROPE: IMMUNOASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)    242
TABLE 205    REST OF EUROPE: IMMUNOASSAY MARKET, BY END USER, 2020–2027 (USD MILLION)    243
11.4    ASIA PACIFIC    243
FIGURE 34    ASIA PACIFIC: IMMUNOASSAY MARKET SNAPSHOT    244
TABLE 206    ASIA PACIFIC: IMMUNOASSAY MARKET, BY COUNTRY, 2020–2027 (USD MILLION)    245
TABLE 207    ASIA PACIFIC: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION)    245
TABLE 208    ASIA PACIFIC: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION)    246
TABLE 209    ASIA PACIFIC: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION)    246
TABLE 210    ASIA PACIFIC: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION)    247
TABLE 211    ASIA PACIFIC: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)    247
TABLE 212    ASIA PACIFIC: IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION)    248
TABLE 213    ASIA PACIFIC: IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION)    248
TABLE 214    ASIA PACIFIC: IMMUNOASSAY MARKET, BY SPECIMEN, 2020–2027 (USD MILLION)    249
TABLE 215    ASIA PACIFIC: IMMUNOASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)    249
TABLE 216    ASIA PACIFIC: IMMUNOASSAY MARKET, BY END USER, 2020–2027 (USD MILLION)    250
11.4.1    JAPAN    250
11.4.1.1    Investments in healthcare technology and research to support growth in Japan    250
TABLE 217    JAPAN: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION)    251
TABLE 218    JAPAN: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION)    251
TABLE 219    JAPAN: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION)    252
TABLE 220    JAPAN: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION)    252
TABLE 221    JAPAN: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)    253
TABLE 222    JAPAN: IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION)    253
TABLE 223    JAPAN: IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION)    254
TABLE 224    JAPAN: IMMUNOASSAY MARKET, BY SPECIMEN, 2020–2027 (USD MILLION)    254
TABLE 225    JAPAN: IMMUNOASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)    255
TABLE 226    JAPAN: IMMUNOASSAY MARKET, BY END USER, 2020–2027 (USD MILLION)    255
11.4.2    CHINA    256
11.4.2.1    Opportunities for growth in China hampered by long product approval and registration processes    256
TABLE 227    CHINA: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION)    257
TABLE 228    CHINA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION)    257
TABLE 229    CHINA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION)    258
TABLE 230    CHINA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION)    258
TABLE 231    CHINA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)    259
TABLE 232    CHINA: IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION)    259
TABLE 233    CHINA: IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION)    260
TABLE 234    CHINA: IMMUNOASSAY MARKET, BY SPECIMEN, 2020–2027 (USD MILLION)    260
TABLE 235    CHINA: IMMUNOASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)    261
TABLE 236    CHINA: IMMUNOASSAY MARKET, BY END USER, 2020–2027 (USD MILLION)    261
11.4.3    INDIA    262
11.4.3.1    Growing medical tourism and healthcare infrastructure will drive use of immunoassays in India    262
TABLE 237    INDIA: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION)    263
TABLE 238    INDIA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION)    263
TABLE 239    INDIA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION)    264
TABLE 240    INDIA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION)    264
TABLE 241    INDIA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)    265
TABLE 242    INDIA: IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION)    265
TABLE 243    INDIA: IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION)    266
TABLE 244    INDIA: IMMUNOASSAY MARKET, BY SPECIMEN, 2020–2027 (USD MILLION)    266
TABLE 245    INDIA: IMMUNOASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)    267
TABLE 246    INDIA: IMMUNOASSAY MARKET, BY END USER, 2020–2027 (USD MILLION)    267"
"11.4.4    AUSTRALIA    268
11.4.4.1    Growing disease incidence and technological development drive market growth    268
TABLE 247    AUSTRALIA: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION)    269
TABLE 248    AUSTRALIA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION)    269
TABLE 249    AUSTRALIA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION)    270
TABLE 250    AUSTRALIA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION)    270
TABLE 251    AUSTRALIA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)    271
TABLE 252    AUSTRALIA: IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION)    271
TABLE 253    AUSTRALIA: IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION)    272
TABLE 254    AUSTRALIA: IMMUNOASSAY MARKET, BY SPECIMEN, 2020–2027 (USD MILLION)    272
TABLE 255    AUSTRALIA: IMMUNOASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)    273
TABLE 256    AUSTRALIA: IMMUNOASSAY MARKET, BY END USER, 2020–2027 (USD MILLION)    273
11.4.5    SOUTH KOREA    274
11.4.5.1    Rising healthcare spending and investments in research fuel market growth    274
TABLE 257    SOUTH KOREA: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION)    274
TABLE 258    SOUTH KOREA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION)    275
TABLE 259    SOUTH KOREA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION)    275
TABLE 260    SOUTH KOREA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION)    276
TABLE 261    SOUTH KOREA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)    276
TABLE 262    SOUTH KOREA: IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION)    277
TABLE 263    SOUTH KOREA: IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION)    277
TABLE 264    SOUTH KOREA: IMMUNOASSAY MARKET, BY SPECIMEN, 2020–2027 (USD MILLION)    278
TABLE 265    SOUTH KOREA: IMMUNOASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)    278
TABLE 266    SOUTH KOREA: IMMUNOASSAY MARKET, BY END USER, 2020–2027 (USD MILLION)    279
11.4.6    INDONESIA    279
11.4.6.1    Indonesia has become a promising market and growth hotspot for foreign investors    279
TABLE 267    INDONESIA: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION)    280
TABLE 268    INDONESIA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION)    280
TABLE 269    INDONESIA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION)    281
TABLE 270    INDONESIA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION)    281
TABLE 271    INDONESIA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)    282
TABLE 272    INDONESIA: IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION)    282
TABLE 273    INDONESIA: IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION)    283
TABLE 274    INDONESIA: IMMUNOASSAY MARKET, BY SPECIMEN, 2020–2027 (USD MILLION)    283
TABLE 275    INDONESIA: IMMUNOASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)    284
TABLE 276    INDONESIA: IMMUNOASSAY MARKET, BY END USER, 2020–2027 (USD MILLION)    284
11.4.7    REST OF ASIA PACIFIC    285
TABLE 277    REST OF ASIA PACIFIC: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION)    286
TABLE 278    REST OF ASIA PACIFIC: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION)    286
TABLE 279    REST OF ASIA PACIFIC: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION)    287
TABLE 280    REST OF ASIA PACIFIC: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION)    287
TABLE 281    REST OF ASIA PACIFIC: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)    288
TABLE 282    REST OF ASIA PACIFIC: IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION)    288
TABLE 283    REST OF ASIA PACIFIC: IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION)    289
TABLE 284    REST OF ASIA PACIFIC: IMMUNOASSAY MARKET, BY SPECIMEN, 2020–2027 (USD MILLION)    289
TABLE 285    REST OF ASIA PACIFIC: IMMUNOASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)    290
TABLE 286    REST OF ASIA PACIFIC: IMMUNOASSAY MARKET, BY END USER, 2020–2027 (USD MILLION)    291
11.5    LATIN AMERICA    291
TABLE 287    LATIN AMERICA: IMMUNOASSAY MARKET, BY COUNTRY, 2020–2027 (USD MILLION)    292
TABLE 288    LATIN AMERICA: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION)    292
TABLE 289    LATIN AMERICA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION)    293
TABLE 290    LATIN AMERICA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION)    293
TABLE 291    LATIN AMERICA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION)    294
TABLE 292    LATIN AMERICA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)    294
TABLE 293    LATIN AMERICA: IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION)    295
TABLE 294    LATIN AMERICA: IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION)    295
TABLE 295    LATIN AMERICA: IMMUNOASSAY MARKET, BY SPECIMEN, 2020–2027 (USD MILLION)    296
TABLE 296    LATIN AMERICA: IMMUNOASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)    296
TABLE 297    LATIN AMERICA: IMMUNOASSAY MARKET, BY END USER, 2020–2027 (USD MILLION)    297
11.5.1    BRAZIL    297
11.5.1.1    Brazil was largest market for immunoassays in LATAM    297
TABLE 298    BRAZIL: IMMUNOASSAY TESTS APPROVED BY ANVISA FOR COVID-19 APPLICATIONS    298
TABLE 299    BRAZIL: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION)    298
TABLE 300    BRAZIL: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION)    299
TABLE 301    BRAZIL: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION)    299
TABLE 302    BRAZIL: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION)    300
TABLE 303    BRAZIL: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)    300
TABLE 304    BRAZIL: IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION)    301
TABLE 305    BRAZIL: IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION)    301
TABLE 306    BRAZIL: IMMUNOASSAY MARKET, BY SPECIMEN, 2020–2027 (USD MILLION)    302
TABLE 307    BRAZIL: IMMUNOASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)    302
TABLE 308    BRAZIL: IMMUNOASSAY MARKET, BY END USER, 2020–2027 (USD MILLION)    303
11.5.2    MEXICO    303
11.5.2.1    Growing lab consolidation to reduce number of labs in Mexico    303
TABLE 309    MEXICO: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION)    304
TABLE 310    MEXICO: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION)    304
TABLE 311    MEXICO: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION)    305
TABLE 312    MEXICO: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION)    305
TABLE 313    MEXICO: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)    306
TABLE 314    MEXICO: IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION)    306
TABLE 315    MEXICO: IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION)    307
TABLE 316    MEXICO: IMMUNOASSAY MARKET, BY SPECIMEN, 2020–2027 (USD MILLION)    307
TABLE 317    MEXICO: IMMUNOASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)    308
TABLE 318    MEXICO: IMMUNOASSAY MARKET, BY END USER, 2020–2027 (USD MILLION)    308
11.5.3    REST OF LATIN AMERICA    309
TABLE 319    REST OF LATIN AMERICA: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION)    309
TABLE 320    REST OF LATIN AMERICA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION)    310
TABLE 321    REST OF LATIN AMERICA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION)    310
TABLE 322    REST OF LATIN AMERICA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION)    311
TABLE 323    REST OF LATIN AMERICA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)    311
TABLE 324    REST OF LATIN AMERICA: IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION)    312
TABLE 325    REST OF LATIN AMERICA: IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION)    312
TABLE 326    REST OF LATIN AMERICA: IMMUNOASSAY MARKET, BY SPECIMEN, 2020–2027 (USD MILLION)    313
TABLE 327    REST OF LATIN AMERICA: IMMUNOASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)    313
TABLE 328    REST OF LATIN AMERICA: IMMUNOASSAY MARKET, BY END USER, 2020–2027 (USD MILLION)    314
11.6    MIDDLE EAST & AFRICA    314
11.6.1    LACK OF SKILLED LAB PERSONNEL AND UNFAVORABLE REIMBURSEMENT POLICIES TO LIMIT GROWTH    314
TABLE 329    MIDDLE EAST & AFRICA: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION)    315
TABLE 330    MIDDLE EAST & AFRICA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION)    315
TABLE 331    MIDDLE EAST & AFRICA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION)    316
TABLE 332    MIDDLE EAST & AFRICA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION)    316
TABLE 333    MIDDLE EAST & AFRICA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)    317
TABLE 334    MIDDLE EAST & AFRICA: IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION)    317
TABLE 335    MIDDLE EAST & AFRICA: IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION)    318
TABLE 336    MIDDLE EAST & AFRICA: IMMUNOASSAY MARKET, BY SPECIMEN, 2020–2027 (USD MILLION)    318
TABLE 337    MIDDLE EAST & AFRICA: IMMUNOASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)    319
TABLE 338    MIDDLE EAST & AFRICA: IMMUNOASSAY MARKET, BY END USER, 2020–2027 (USD MILLION)    320
12    COMPETITIVE LANDSCAPE    321
12.1    OVERVIEW    321
12.2    KEY PLAYER STRATEGIES/RIGHT TO WIN    321
12.2.1    OVERVIEW OF STRATEGIES ADOPTED BY KEY IMMUNOASSAY PRODUCT MANUFACTURERS    321
12.3    REVENUE ANALYSIS    322
FIGURE 35    REVENUE ANALYSIS OF KEY PLAYERS    323
12.4    MARKET SHARE ANALYSIS    323
TABLE 339    IMMUNOASSAY MARKET: DEGREE OF COMPETITION    324
FIGURE 36    MARKET SHARE ANALYSIS, 2021    324
12.5    COMPANY EVALUATION MATRIX    325
12.5.1    STARS    325
12.5.2    EMERGING LEADERS    325
12.5.3    PERVASIVE PLAYERS    325
12.5.4    PARTICIPANTS    325
FIGURE 37    IMMUNOASSAY MARKET: COMPANY EVALUATION QUADRANT    326
12.6    COMPANY EVALUATION QUADRANT (SMES/START-UPS)    327
12.6.1    PROGRESSIVE COMPANIES    327
12.6.2    STARTING BLOCKS    327
12.6.3    RESPONSIVE COMPANIES    327
12.6.4    DYNAMIC COMPANIES    327
FIGURE 38    IMMUNOASSAY MARKET: COMPANY EVALUATION QUADRANT FOR START-UPS/SMES    328
12.7    COMPANY FOOTPRINT ANALYSIS    329
TABLE 340    COMPANY FOOTPRINT    329
TABLE 341    COMPANY PRODUCT FOOTPRINT    329
TABLE 342    COMPANY REGIONAL FOOTPRINT    330
12.8    COMPETITIVE BENCHMARKING    331
TABLE 343    IMMUNOASSAY MARKET: DETAILED LIST OF KEY START-UPS/SMES    331
12.9    COMPETITIVE SCENARIO    332
12.9.1    PRODUCT LAUNCHES & APPROVALS    332
TABLE 344    IMMUNOASSAY MARKET: PRODUCT LAUNCHES & APPROVALS, 2019–2022    332
12.9.2    DEALS    333
TABLE 345    IMMUNOASSAY MARKET: DEALS, 2019–2022    333
12.9.3    OTHER DEVELOPMENTS    334
TABLE 346    IMMUNOASSAY MARKET: OTHER DEVELOPMENTS, 2019–2022    334
13    COMPANY PROFILES    335
(Business overview, Products offered, Recent Developments, MNM view)*
13.1    MAJOR PLAYERS    335
13.1.1    ABBOTT LABORATORIES    335
TABLE 347    ABBOTT LABORATORIES: BUSINESS OVERVIEW    335
FIGURE 39    ABBOTT LABORATORIES: COMPANY SNAPSHOT (2021)    336
13.1.2    ROCHE DIAGNOSTICS    340
TABLE 348    F. HOFFMANN-LA ROCHE: BUSINESS OVERVIEW    340
FIGURE 40    F. HOFFMANN-LA ROCHE: COMPANY SNAPSHOT (2021)    341
13.1.3    SIEMENS HEALTHINEERS AG    347
TABLE 349    SIEMENS HEALTHINEERS AG: BUSINESS OVERVIEW    347
FIGURE 41    SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2021)    348
13.1.4    DANAHER CORPORATION    352
TABLE 350    DANAHER CORPORATION: BUSINESS OVERVIEW    352
FIGURE 42    DANAHER CORPORATION: COMPANY SNAPSHOT (2021)    353
13.1.5    THERMO FISHER SCIENTIFIC INC.    357
TABLE 351    THERMO FISHER SCIENTIFIC INC.: BUSINESS OVERVIEW    357
FIGURE 43    THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2021)    358
13.1.6    PERKINELMER, INC.    362
TABLE 352    PERKINELMER, INC.: BUSINESS OVERVIEW    362
FIGURE 44    PERKINELMER, INC.: COMPANY SNAPSHOT (2021)    363
13.1.7    BECTON, DICKINSON AND COMPANY    366
TABLE 353    BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW    366
FIGURE 45    BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2021)    367
13.1.8    DIASORIN S.P.A.    370
TABLE 354    DIASORIN S.P.A.: BUSINESS OVERVIEW    370
FIGURE 46    DIASORIN S.P.A.: COMPANY SNAPSHOT (2021)    371
13.1.9    BIO-RAD LABORATORIES, INC.    374
TABLE 355    BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW    374
FIGURE 47    BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2021)    375
13.1.10    QUIDEL CORPORATION    378
TABLE 356    QUIDEL CORPORATION: BUSINESS OVERVIEW    378
FIGURE 48    QUIDEL CORPORATION: COMPANY SNAPSHOT (2021)    379
13.1.11    ORTHO CLINICAL DIAGNOSTICS HOLDINGS PLC    384
TABLE 357    ORTHO CLINICAL DIAGNOSTICS HOLDINGS PLC: BUSINESS OVERVIEW    384
FIGURE 49    ORTHO CLINICAL DIAGNOSTICS HOLDINGS PLC: COMPANY SNAPSHOT (2021)    385
13.1.12    BIOMÉRIEUX    389
TABLE 358    BIOMÉRIEUX: BUSINESS OVERVIEW    389
FIGURE 50    BIOMÉRIEUX: COMPANY SNAPSHOT (2021)    390
13.1.13    QIAGEN    394
TABLE 359    QIAGEN: BUSINESS OVERVIEW    394
FIGURE 51    QIAGEN: COMPANY SNAPSHOT (2021)    395
13.1.14    SYSMEX CORPORATION    397
TABLE 360    SYSMEX CORPORATION: BUSINESS OVERVIEW    397
FIGURE 52    SYSMEX CORPORATION: COMPANY SNAPSHOT (2021)    398
13.1.15    AGILENT TECHNOLOGIES    401
TABLE 361    AGILENT TECHNOLOGIES: BUSINESS OVERVIEW    401
FIGURE 53    AGILENT TECHNOLOGIES: COMPANY SNAPSHOT (2021)    402
13.1.16    MINDRAY MEDICAL INTERNATIONAL COMPANY    404
TABLE 362    MINDRAY MEDICAL INTERNATIONAL COMPANY: BUSINESS OVERVIEW    404
13.2    OTHER PLAYERS    406
13.2.1    MERCK KGAA    406
13.2.2    MERIDIAN BIOSCIENCE    407
13.2.3    BIO-TECHNE    408
13.2.4    CELLABS    409
13.2.5    ABNOVA CORPORATION    410
13.2.6    J. MITRA & CO.    410
13.2.7    TOSOH CORPORATION (TOSOH BIOSCIENCES)    411
13.2.8    CELL SCIENCES    411
13.2.9    ENZO BIOCHEM    412
13.2.10    CREATIVE DIAGNOSTICS    413
13.2.11    BOSTER BIOLOGICAL TECHNOLOGY    413
13.2.12    ELABSCIENCE    414
13.2.13    WAK-CHEMIE MEDICAL    414
13.2.14    SERA CARE    415
13.2.15    EPITOPE DIAGNOSTICS    415
13.2.16    KAMIYA BIOMEDICAL COMPANY    416
13.2.17    GYROS PROTEIN TECHNOLOGIES    416
13.2.18    TRIVITRON HEALTHCARE    417
13.2.19    INBIOS INTERNATIONAL, INC.    417
*Details on Business overview, Products offered, Recent Developments, MNM view might not be captured in case of unlisted companies.
14    APPENDIX    418
14.1    INSIGHTS FROM INDUSTRY EXPERTS    418
14.2    DISCUSSION GUIDE    419
14.3    KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL    426
14.4    AVAILABLE CUSTOMIZATIONS    428
14.5    RELATED REPORTS    428
14.6    AUTHOR DETAILS    430"